ScreenerHero

VRAX Virax Biolabs Group Limited

NAS · US · Healthcare · Biotechnology · viraxbiolabs.com
2.110USD+3.94%Mkt Cap: 2.84M $P/E: —

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the U…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.84M USD
Enterprise Value-5.17M USD
Revenue (TTM)12.42K USD
Gross Profit7.69K USD
Net Income (TTM)-5.02M USD
Revenue/Share0.03 USD
Last Price2.110 USD
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees26
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.34
PEG—
EV/EBITDA0.85
EV/Revenue-416.20
P/S219.78
P/B0.16
EPS (TTM)-12.64
EPS (Forward)-6.00
52W Range
1.8301% of range21.75
52W High21.75 USD
52W Low1.830 USD
Profitability
Gross Margin61.90%
Oper. Margin-35264.92%
EBITDA Margin0.00%
Profit Margin-40439.10%
ROE-66.30%
ROA-60.35%
Growth
Revenue Growth684.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.62M USD
CapEx (TTM)255.83K USD
FCF Margin-27988.54%
FCF Yield-122.52%
Net Debt-6.10M USD
Net Debt/EBITDA1.01
Balance Sheet
Debt/Equity0.05
Current Ratio9.97
Quick Ratio9.55
Book Value/Sh13.08 USD
Cash/Share11.25 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJun 26, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.34M
Float529.04K
Insiders1.58%
Institutions1.99%
Short Interest
Short Ratio0.0d
Short % Float2.30%
Short % Out.2.27%
Shares Short30.52K
Short (prev mo.)23.36K
Technical
SMA 502.710 (-22.1%)
SMA 2004.638 (-54.5%)
Beta1.39
S&P 52W Chg15.78%
Avg Vol (30d)766.89K
Avg Vol (10d)312.10K
Technical Indicators
RSI (14)37.4
MACD-0.1950
MACD Signal-0.1813
MACD Hist.-0.0138
BB Upper2.891 USD
BB Middle2.442 USD
BB Lower1.993 USD
BB Width36.75%
ATR (14)0.3213 USD
Vol Ratio (20d)1.45x